Proactive Investors - Run By Investors For Investors

BATM's Ador Diagnostics receives US$14.5mln initial investment

Dr Zvi Marom, chief executive of BATM Advanced Communications Limited (LON:BVC), tells Proactive London their joint venture company Ador Diagnostics has received the first tranche of a US$30mln investment.

Marom says they'll use the US$14.5mln to develop the NATlab reader, a rapid-results molecular biology diagnostics system, with the rest of the investment due in 2020.

 
Meet Clinigen Group PLC, MaxCyte, Cello Health PLC, Oncimmune and Silence Therapeutics PLC at our event, London , 11 July 2019. Register here »
View full BVC profile View Profile

BATM Advanced Communications Ltd Timeline

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use